Literature DB >> 9353938

The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms.

Zhonghe Sun1, Angelo Scorpio1, Ying Zhang1.   

Abstract

The antituberculosis drug pyrazinamide (PZA) needs to be converted into pyrazinoic acid (POA) by the bacterial pyrazinamidase (PZase) in order to show bactericidal activity against Mycobacterium tuberculosis. M. avium is naturally resistant to PZA. To investigate whether this natural resistance to PZA is due to inability of the M. avium PZase to convert PZA to bactericidal POA, the M. avium PZase gene (pncA) was cloned by using the M. tuberculosis pncA gene as a probe. Sequence analysis showed that the M. avium pncA gene is 561 bp long, encoding a protein with a predicted size of about 19.8 kDa; but Western blotting showed that the M. avium PZase migrated as a 24 kDa band when expressed in M. bovis BCG and Escherichia coli. Sequence comparison revealed that M. avium PZase has 67.7% and 32.8% amino acid identity with the corresponding enzymes from M. tuberculosis and E. coli, respectively. Southern blot analysis with the M. avium pncA gene as a probe showed that M. terrae, M. gastri, M. marinum, M. fortuitum, M. xenopi, M. gordonae, M. szulgai, M. celatum and M. kansasii have close pncA homologues, whereas M. chelonae and M. smegmatis did not give significant hybridization signals. Transformation with the M. avium pncA gene conferred PZA susceptibility to PZA-resistant M. tuberculosis complex organisms, indicating that the nonsusceptibility of M. avium to PZA is not due to an ineffective PZase enzyme, but appears to be related to other factors such as transport of POA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353938     DOI: 10.1099/00221287-143-10-3367

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  12 in total

1.  Mycobacterium smegmatis has two pyrazinamidase enzymes, PncA and pzaA.

Authors:  M Guo; Z Sun; Y Zhang
Journal:  J Bacteriol       Date:  2000-07       Impact factor: 3.490

2.  Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Authors:  Helena I Boshoff; Valerie Mizrahi; Clifton E Barry
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

3.  Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Y Zhang; A Scorpio; H Nikaido; Z Sun
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

4.  Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.

Authors:  David C Alexander; Jennifer H Ma; Jennifer L Guthrie; Joanne Blair; Pam Chedore; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2012-08-15       Impact factor: 5.948

5.  Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides.

Authors:  H I Boshoff; V Mizrahi
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

6.  Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.

Authors:  Z Sun; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Antibacterial activities of naturally occurring compounds against Mycobacterium avium subsp. paratuberculosis.

Authors:  Stella Y Y Wong; Irene R Grant; Mendel Friedman; Christopher T Elliott; Chen Situ
Journal:  Appl Environ Microbiol       Date:  2008-08-01       Impact factor: 4.792

8.  Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.

Authors:  Silvana C Ngo; Oren Zimhony; Woo Jin Chung; Halimah Sayahi; William R Jacobs; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

9.  Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Ruijuan Zheng; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

Review 10.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.